<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-146341" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biphenotypic Sinonasal Sarcoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ghias</surname>
            <given-names>Adeeba</given-names>
          </name>
          <aff>Tripler Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chislett</surname>
            <given-names>Sean</given-names>
          </name>
          <aff>Tripler Army Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adeeba Ghias declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sean Chislett declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-146341.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Biphenotypic sinonasal sarcoma (BSNS) is an emerging subtype of sinonasal malignancy. It has not been previously well-studied but has characteristic gene fusion products and associated phenotypic features unique to it. Although rare, it has the potential to become large and infiltrate into bone over a prolonged period, with nonspecific preceding symptoms. It was first described in 2012, and more studies are needed before definitive decisions can be made regarding adjuvant treatments in addition to surgery. This activity reviews the evaluation, management, and overarching principles of BSNS and highlights the role of the healthcare team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the typical presentation of biphenotypic sinonasal sarcoma and its distinctions from other sinonasal malignancies.</p></list-item><list-item><p>Outline the typical immunohistochemical findings for biphenotypic sinonasal sarcoma.</p></list-item><list-item><p>Summarize new developments in the identification of biphenotypic sinonasal sarcoma via molecular testing methods.</p></list-item><list-item><p>Explain the importance of distinguishing biphenotypic sinonasal sarcoma from other malignancies in the differential diagnosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=146341&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=146341">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-146341.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Sinonasal malignancies only constitute 1-5% of head and neck malignancies but have a wide differential diagnosis and relatively non-specific symptoms.<xref ref-type="bibr" rid="article-146341.r1">[1]</xref><xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r3">[3]</xref><xref ref-type="bibr" rid="article-146341.r4">[4]</xref>&#x000a0;Sinonasal malignancies are most frequently diagnosed as&#x000a0;squamous cell carcinoma (36 to 58%), followed by adenocarcinoma, mucosal melanoma, adenoid cystic carcinoma, and esthesioneuroblastoma.<xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r5">[5]</xref></p>
        <p>A lesser-known and recently classified entity is biphenotypic sinonasal carcinoma (BSNS), which will be reviewed in this article. BSNS was first described in 2012 as "low-grade sinonasal sarcoma with neural and myogenic features" and was first recognized in the 2017 4th edition of the World Health Organization (WHO) Classification of Head and Neck Tumors.<xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r7">[7]</xref> Although it is a slow-growing and low-grade malignancy of the upper aerodigestive&#x000a0;tract, BSNS is locally aggressive.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r10">[10]</xref>&#x000a0;About 20% of patients already have bony invasion at&#x000a0;presentation in areas like the orbit (25%) and the cribriform plate (10%).<xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r5">[5]</xref><xref ref-type="bibr" rid="article-146341.r11">[11]</xref>&#x000a0;</p>
        <p>Cervical nodal metastasis&#x000a0;is&#x000a0;rarely demonstrated in any sinonasal malignancy and has not yet been demonstrated in patients with BSNS.<xref ref-type="bibr" rid="article-146341.r2">[2]</xref>&#x000a0;The tumors can approach up to 4 cm and are most commonly found in the nasal cavity or ethmoid sinus, followed by the sphenoid sinus, in frequency.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r12">[12]</xref><xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r6">[6]</xref>&#x000a0;The&#x000a0;maxillary sinus is the most common site for any sinonasal primary, but the ethmoid sinus contains the primary in 5&#x000a0;to 15% of patients.<xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;In BSNS, however, the incidence of ethmoid involvement is significantly greater but not yet quantified.<xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;</p>
        <p>Unlike squamous cell carcinoma, with an anticipated&#x000a0;5-year survival of only 25 to 50%, there have been no patients with BSNS who developed metastases, and only one death has been recorded&#x000a0;in the literature.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r8">[8]</xref>&#x000a0;It is&#x000a0;unclear what percentage of sinonasal malignancies are later diagnosed as&#x000a0;BSNS, as the malignancy was previously classified under various entities, including but not limited to pseudofibrosarcoma, angiofibroma, and leiomyosarcoma.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r7">[7]</xref><xref ref-type="bibr" rid="article-146341.r13">[13]</xref><xref ref-type="bibr" rid="article-146341.r6">[6]</xref>&#x000a0;Just over 100 cases have been described in the existing literature, which represents a combination of cases derived from retrospective reviews of specimens&#x000a0;and from more current case reports.<xref ref-type="bibr" rid="article-146341.r10">[10]</xref></p>
      </sec>
      <sec id="article-146341.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are no specific risk factors for the development of BSNS. Broadly, hazardous industrial chemicals used in textiles, furniture, and leather processing and production are risk factors for all tumors of the paranasal sinuses.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;</p>
        <p>At the genetic level, fluorescence-in-situ hybridization (FISH) is remarkable for a characteristic PAX3-MAML fusion protein that leads to the development of BSNS pathology.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r12">[12]</xref></p>
      </sec>
      <sec id="article-146341.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Multiple studies have demonstrated a female preponderance to BSNS, with a ratio of 1.8:1 up to 2.27:1 in females versus males.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r14">[14]</xref>&#x000a0;While the mean age is 50-52 years old, the range is between the mid-20s to mid-80s.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref></p>
      </sec>
      <sec id="article-146341.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>PAX3 is a gene involved in developing skeletal muscle, the central nervous system, and neural crest cells. In BSNS, fusion proteins due to the interaction of PAX3 with MAML drive amplification of neuroepithelial expression.<xref ref-type="bibr" rid="article-146341.r15">[15]</xref></p>
      </sec>
      <sec id="article-146341.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathologic examination of BSNS demonstrates hypercellular, uniform, long spindle-shaped cells in a fascicular pattern occasionally described as a "herringbone" configuration.<xref ref-type="bibr" rid="article-146341.r6">[6]</xref>&#x000a0;Nuclei will appear tapered, and despite the hypercellularity, there are almost no mitoses. Necrosis, ulceration, and hemorrhage are not common.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r7">[7]</xref>&#x000a0;</p>
        <p>The cytoplasm of involved cells is scant and pale, and the tumor itself appears unencapsulated.<xref ref-type="bibr" rid="article-146341.r11">[11]</xref>&#x000a0;There can be foci of respiratory epithelium entrapped in tumor cells, creating a pseudoglandular appearance.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref>&#x000a0;</p>
        <p>Infiltrative tumors will be embedded in a bony matrix. <xref ref-type="bibr" rid="article-146341.r8">[8]</xref>&#x000a0;Vascular staghorn formations are common but can confound the diagnosis by expanding the differential diagnosis.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r7">[7]</xref><xref ref-type="bibr" rid="article-146341.r15">[15]</xref> Identifying elements of both neural and myogenic differentiation with immunophenotyping, patchy or diffuse S-100 and smooth muscle actin (SMA) expression, and SOX-10 negativity are key in confirming the diagnosis.<xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref></p>
        <p>Genetic features displayed by BSNS involve chromosomal translation t(2,4) and a fusion protein formed by the interaction of the PAX3-MAML genes.<xref ref-type="bibr" rid="article-146341.r6">[6]</xref><xref ref-type="bibr" rid="article-146341.r8">[8]</xref>&#x000a0;The PAX3-MAML fusion is highly reliable in diagnosing BSNS, as it is present in 79 to 96% of cases.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref>&#x000a0;The fusion of PAX3 with other genes, NCOA1 and FOXO1, suggests a more aggressive rhabdomyoblastic variant due to different amplification targets downstream.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r15">[15]</xref></p>
      </sec>
      <sec id="article-146341.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common presenting symptoms are progressive nasal obstruction, intermittent nasal congestion, anosmia, facial swelling and pain, epistaxis, anosmia, periorbital numbness, intermittent blurry vision, and rhinorrhea.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r11">[11]</xref><xref ref-type="bibr" rid="article-146341.r10">[10]</xref><xref ref-type="bibr" rid="article-146341.r13">[13]</xref> Patients with advanced tumors may also have epiphora, diplopia, proptosis, and cerebrospinal fluid (CSF) rhinorrhea&#x000a0;depending on specific subsite involvement.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r11">[11]</xref><xref ref-type="bibr" rid="article-146341.r1">[1]</xref></p>
        <p>In some patients, the presentation can be confused with sinusitis, as patients present with secondary mucopurulent sinonasal drainage.<xref ref-type="bibr" rid="article-146341.r2">[2]</xref> Given these nonspecific symptoms, patients are usually diagnosed at an advanced stage, similar to many other sinonasal tumors. Trismus due to invasion into the pterygoids, cranial nerve palsies, and hearing loss due to eustachian tube invasion may be associated with advanced disease and a worse prognosis.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref></p>
      </sec>
      <sec id="article-146341.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Both computed tomography (CT) and magnetic resonance imaging (MRI) are used in assessing sinonasal tumors to detect their presence, size, and invasiveness. In patients with BSNS, CT generally demonstrates a sinonasal mass with areas of hyperostosis, erosion of adjacent bony structures, and often post-obstructive sinus opacification.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref></p>
        <p>On MRI, the tumor is isointense on T1 and T2, appearing similar to gray matter on T2. BSNS enhances heterogeneously with contrast.<xref ref-type="bibr" rid="article-146341.r14">[14]</xref><xref ref-type="bibr" rid="article-146341.r12">[12]</xref>&#x000a0;The enhancement pattern is likely due to the admixture of glandular components, which can be directly visualized histologically.<xref ref-type="bibr" rid="article-146341.r12">[12]</xref>&#x000a0;There is restriction on diffusion-weighted imaging.&#x000a0;</p>
        <p>Positron emission tomography (PET) scans may be ordered to determine the presence of metastases; however, the utility is limited in BSNS as these tumors display none-to-low PET avidity, and they rarely, if ever, metastasize either locally or distantly.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r12">[12]</xref></p>
      </sec>
      <sec id="article-146341.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment, as discussed further below, is primarily surgical. The utility of radiation therapy is unclear. Chemotherapy does not seem to add any therapeutic benefit.</p>
      </sec>
      <sec id="article-146341.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for BSNS includes other uncommon sinonasal tumors, and it has been incorrectly diagnosed previously due to paucity of knowledge and resultant gaps&#x000a0;in&#x000a0;histopathological study.&#x000a0;</p>
        <p>Sinonasal tumors with similar presenting features include solitary fibrous tumor (SFT), fibromatosis, myofibrosarcoma, schwannoma, leiomyosarcoma, synovial sarcoma (SS), malignant peripheral nerve sheath tumor with or without rhabdomyoblastic features (Triton tumor), glomangiopericytoma, and inverted papilloma.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r7">[7]</xref><xref ref-type="bibr" rid="article-146341.r11">[11]</xref><xref ref-type="bibr" rid="article-146341.r10">[10]</xref></p>
        <p>Although difficult to separate visually due to overlapping presentation, the histopathological analysis provides a definitive ability to classify rare sinonasal tumors. In preparation for these comparisons between BSNS and other tumors in the differential diagnosis, recall briefly the features of BSNS - hypercellular, spindle-shaped, patchy or diffuse S100 and SMA staining, lack of SOX10 staining, PAX3-MAML fusion, and rare mitoses or necrosis.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Solitary fibrous tumors, unlike BSNS, express cytokeratin.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fibrosarcomas are less cellular and not S-100 positive.<xref ref-type="bibr" rid="article-146341.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Schwannomas and nerve tumors stain positive for SOX1.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Leiomyosarcoma does not demonstrate S-100 positivity, and features include perinuclear halos around cigar-shaped nuclei.<xref ref-type="bibr" rid="article-146341.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Synovial sarcoma can mimic BSNS due to the presence of pseudoglandular structures.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref>&#x000a0;However, unlike BSNS, it also has positive cytokeratin expression and additionally thick collagen bundles.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref> The chromosomal translocation in synovial sarcoma t(x;19)(p11;q11) leads to a characteristic SS18 rearrangement that is diagnostic for synovial sarcoma.&#x000a0;It is diffusely S100 positive.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fibromatosis, specifically neurofibromatosis type 1, is strongly associated with Triton tumor. While Triton tumor has features of rhabdomyosarcoma in addition to neural features, it is seen in patients slightly younger than those with BSNS.<xref ref-type="bibr" rid="article-146341.r11">[11]</xref>&#x000a0;The studied age range falls between 30 and 50 years of age.<xref ref-type="bibr" rid="article-146341.r11">[11]</xref> Its presentation is characterized by rapid growth and resultant mass effect, while histology demonstrates hyperchromasia, nuclear atypia, widespread mitoses, and necrosis.&#x000a0;Despite these differences from BSNS, lower-grade peripheral nerve sheath tumors may look nearly identical under the microscope.<xref ref-type="bibr" rid="article-146341.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Glomangiopericytoma is more epithelioid, does not stain positive for S100, and has a short instead of long fascicular pattern with round or ovoid nuclei.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The invaginated respiratory epithelial component of BSNS is also seen in inverted papilloma, but inverted papilloma has a significantly more prominent glandular pattern and no spindle cell proliferation.<xref ref-type="bibr" rid="article-146341.r3">[3]</xref><xref ref-type="bibr" rid="article-146341.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>None of the listed etiologies in the differential demonstrate PAX3-MAML fusion on fluorescence in-situ hybridization (FISH), which is diagnostic for BSNS.&#x000a0;</p>
        <p>Synovial sarcoma, fibrosarcoma, and low-grade malignant peripheral nerve sheath tumors are most often misdiagnosed in place of BSNS.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref></p>
      </sec>
      <sec id="article-146341.s11" sec-type="Surgical Oncology">
        <title>Surgical Oncology</title>
        <p>Surgical resection is the primary therapy for BSNS. However, the operative surgeon may need to leave positive margins of the tumor to limit the violation of critical structures like the orbit or skull base.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r4">[4]</xref><xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref></p>
        <p>Both endoscopic and open-surgical approaches have been described, and the most appropriate approach depends on the location and extent of the tumor and the surgeon's preference. Open approaches include bifrontal craniotomy and lateral rhinotomy.<xref ref-type="bibr" rid="article-146341.r10">[10]</xref><xref ref-type="bibr" rid="article-146341.r13">[13]</xref></p>
        <p>If present, resulting skull base defects may be repaired with autologous tissue, such as a pedicled pericranial flap or synthetic dural repair grafts.<xref ref-type="bibr" rid="article-146341.r13">[13]</xref> Due to the low rate of nodal metastasis for all sinonasal malignancies, elective neck dissection is not recommended.<xref ref-type="bibr" rid="article-146341.r4">[4]</xref></p>
      </sec>
      <sec id="article-146341.s12" sec-type="Radiation Oncology">
        <title>Radiation Oncology</title>
        <p>There is no guidance regarding neoadjuvant, adjuvant, or salvage radiation dosing or technique for BSNS. Treatment plans have been very case-specific, and radiation has thus far been utilized as adjuvant therapy, both prophylactically and for positive surgical margins.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r12">[12]</xref>&#x000a0;</p>
        <p>Due to the few cases reported in the literature and the lack of BSNS-specific photon radiotherapy or proton beam therapy (PBT) studies, no specific recommendations can be made regarding adjuvant photon radiation or proton beam therapy. However, based on broad studies of all sinonasal tumors, adjuvant radiation (photon or proton beam) may be considered in patients with advanced T-stage, bony or neural invasion, dural or intracranial involvement, positive margins, or tumors that cannot be completely resected due to high surgical&#x000a0;morbidity.<xref ref-type="bibr" rid="article-146341.r2">[2]</xref><xref ref-type="bibr" rid="article-146341.r4">[4]</xref> Given the&#x000a0;low nodal metastatic rate, prophylactic cervical irradiation is not recommended.<xref ref-type="bibr" rid="article-146341.r4">[4]</xref></p>
      </sec>
      <sec id="article-146341.s13" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Chemotherapy has been used in treating 12% of patients with BSNS, although there is no guiding evidence for its use.<xref ref-type="bibr" rid="article-146341.r14">[14]</xref> Some reported regimens include cisplatin, carboplatin, or 5-fluorouracil with concurrent radiotherapy.&#x000a0;However, these regimens were studied in patients with unresectable T4b sinonasal tumors and lymphoma, sarcoma, melanoma, and esthesioneuroblastoma.<xref ref-type="bibr" rid="article-146341.r16">[16]</xref> There are no representative studies on chemotherapeutic outcomes&#x000a0;in the management of BSNS.</p>
      </sec>
      <sec id="article-146341.s14" sec-type="Staging">
        <title>Staging</title>
        <p>Before establishing&#x000a0;the AJCC staging system, Ohngren attempted to classify infrastructure versus suprastructure tumors based on a theoretical line drawn between the angle of the mandible to the medial canthus. By separating the superomedial/superolateral and inferomedial/inferolateral&#x000a0;sites of the paranasal sinuses, he theorized that those with suprastructure involvement of the eye, skull base, pterygoid musculature/bone, and infratemporal fossae had a poorer prognosis.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref></p>
        <p>The 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual describes primary tumor staging for sinonasal tumors of the maxillary sinus and nasal cavity/ethmoid sinus only since the involvement of the frontal and/or sphenoid sinuses automatically qualifies the tumor as being T4a.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;</p>
        <p>Only staging for the nasal cavity and ethmoid subsites will be reviewed since BSNS has not been reported in the maxillary sinus. A T1 tumor involves only the nasal cavity or an isolated ethmoid sinus and may or may not invade bone.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref> A T2 tumor extends to involve adjacent structures in the nasoethmoidal complex and may or may not invade bone, or it invades multiple subsites within a single region. A T3 tumor invades high-risk structures immediately adjacent to the ethmoid sinus, including the medial wall or floor of the orbit, maxillary sinus, palate, and cribriform plate.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref></p>
        <p>Tumors within the T4 category are divided into T4a and T4b. T4a involves anterior orbital contents, the skin of the nose and/or cheek, and to a minimal extent, the anterior cranial fossa, pterygoids, frontal sinuses, or sphenoid sinuses. T4b indicates that the tumor has extended into the cranial vault, involving the orbital apex, cranial nerves, nasopharynx, dura, brain, middle cranial fossa, and/or the clivus.</p>
        <p>Nodal staging guides overall staging. Metastasis to a single node on the same side as the tumor, as long as it measures less than 3 cm, is staged as N1. <xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;However, if one ipsilateral node measures between 3 and 6 cm, the tumor is classified as N2a.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;Once the patient develops multiple ipsilateral nodes, all less than 6 cm, the tumor is staged as N2b.&#x000a0;N2c entails metastasis to contralateral or bilateral nodes, still less than 6 cm in the greatest dimension.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;Any lymph node greater than 6 cm qualifies as N3.</p>
        <p>An overall stage is assigned based on the tumor, nodal, and metastasis (TNM) staging. A T1N0M0 tumor is stage 1, and T2N0M0 is stage 2.&#x000a0;Stage 3 includes both T3N0M0 tumors and T1/2/3 tumors with N1 nodal staging.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;Stage 4 is divided into A/B/C to convey tumor extent. Stage 4A tumors include T4aN0M0, T4aN1M0, or T4aN2M0, as well as N2 nodal staging for T1/2/3 without metastasis.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;</p>
        <p>Stage 4B tumors are any T stage with N3 nodal status and T4b tumors with any nodal status N0/1/2/3, without metastasis.&#x000a0;If the patient has a distant metastasis, they are staged as M1 with an overall stage of 4C, regardless of the T or N staging.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref></p>
      </sec>
      <sec id="article-146341.s15" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Based on the limited studies into the behavior of BSNS, the prognosis is unclear. However, the 5-year survival is much likely higher than the reported 25-50% 5-year survival for SCC in the paranasal sinuses.<xref ref-type="bibr" rid="article-146341.r5">[5]</xref>&#x000a0;Out of around 100 cases discussed in the literature, the reported recurrence rate is 32 to 40%.<xref ref-type="bibr" rid="article-146341.r12">[12]</xref>&#x000a0;Only one death has occurred due to a second recurrence and intracranial invasion.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref><xref ref-type="bibr" rid="article-146341.r13">[13]</xref><xref ref-type="bibr" rid="article-146341.r9">[9]</xref><xref ref-type="bibr" rid="article-146341.r3">[3]</xref>&#x000a0;</p>
        <p>The recurrence-free range was one year to 9 years.<xref ref-type="bibr" rid="article-146341.r11">[11]</xref> In one series of 5 patients, two patients had a recurrence that was treated with revision surgery, and one of these patients additionally underwent adjuvant proton beam therapy.<xref ref-type="bibr" rid="article-146341.r12">[12]</xref> The biologic potential is unknown due to ongoing study of the downstream effects of gene fusion that lead to the characteristic presentation of BSNS.<xref ref-type="bibr" rid="article-146341.r9">[9]</xref></p>
      </sec>
      <sec id="article-146341.s16" sec-type="Complications">
        <title>Complications</title>
        <p>There are few reported direct complications of BSNS due to its slow growth pattern. The most commonly reported surgical morbidity is recurrence.<xref ref-type="bibr" rid="article-146341.r8">[8]</xref> Other postoperative complications include blurry vision, loss of vision, cerebrospinal fluid (CSF) leak, pneumocephalus, postoperative infection, necrosis of autologous skull base repair flap, continued nasal congestion, and frontal sinus outflow obstruction.&#x000a0;Regarding skull base defect repair failure, revision defect repair can be completed with alternative autologous tissue flaps or grafts, including a pericranial flap, nasoseptal flap, or tensor fascia lata graft.<xref ref-type="bibr" rid="article-146341.r13">[13]</xref></p>
      </sec>
      <sec id="article-146341.s17" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Postoperative care after endoscopic surgery for BSNS is similar to standard postoperative care for other endoscopic sinonasal and skull base procedures, including sinus precautions and endoscopic debridements. Appropriate rehabilitation services should be provided pending the degree of disability in the postoperative period and if the patient had complications from radiation therapy.</p>
      </sec>
      <sec id="article-146341.s18" sec-type="Consultations">
        <title>Consultations</title>
        <p>If the tumor displays orbital or intracranial invasion, ophthalmology and neurosurgery should be consulted, respectively. If there is an extensive disease or positive margins, radiation oncology should be consulted for further adjuvant treatment planning.&#x000a0;As with any other malignancy, all new BSNS cases should be presented at a multidisciplinary tumor board.</p>
      </sec>
      <sec id="article-146341.s19" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>There is ongoing research on BSNS and the gene rearrangements that cause BSNS that could further elucidate the behavior of this particular pathology.</p>
        <p>The tumor is often mistaken for other pathologies. Therefore, its genetic composition and staging should be closely examined to provide an accurate prognosis and treatment plan for the patient.</p>
      </sec>
      <sec id="article-146341.s20" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although surgery is the primary treatment modality of choice, optimal treatment of any sinonasal malignancy, BSNS included, involves collaboration with other services and members of an interprofessional healthcare team. It is important to review imaging for these tumors with a radiologist, specifically a neuroradiologist if available, to help determine tumor extent and possible involvement of adjacent structures.</p>
        <p>If the tumor is extensive at the time of presentation, which it often is, consultations for ophthalmology and neurosurgery should be considered to help in surgical planning. Furthermore, just as with any other malignancy, all new BSNS cases should be formally discussed at a multi-disciplinary tumor board meeting. Post-operatively, the patient may require an intensive care unit stay for frequent neurologic monitoring. In any post-operative admission, communication between the hospitalist medicine team, nursing staff, and floor technicians is vital for excellent patient care.</p>
      </sec>
      <sec id="article-146341.s21">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=146341&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=146341">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/biphenotypic-sinonasal-sarcoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=146341">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/146341/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=146341">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-146341.s22">
        <title>References</title>
        <ref id="article-146341.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sethi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cody</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Farhat</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Pool</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Katabi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Biphenotypic sinonasal sarcoma: Report of 3 cases with a review of literature.</article-title>
            <source>Hum Pathol (N Y)</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>24</volume>
            <pub-id pub-id-type="pmid">34660202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Awan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Junaid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Qadeer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hassan</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Management of sinonasal tumors: prognostic factors and outcomes: a 10 year experience at a tertiary care hospital.</article-title>
            <source>Indian J Otolaryngol Head Neck Surg</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>Suppl 1</issue>
            <fpage>155</fpage>
            <page-range>155-9</page-range>
            <pub-id pub-id-type="pmid">24427634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreasen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hellquist</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rinaldo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sk&#x000e1;lov&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Willems</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferlito</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity.</article-title>
            <source>Virchows Arch</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>473</volume>
            <issue>5</issue>
            <fpage>615</fpage>
            <page-range>615-626</page-range>
            <pub-id pub-id-type="pmid">30109475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Contrera</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Woody</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sindwani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burkey</surname>
                <given-names>BB</given-names>
              </name>
            </person-group>
            <article-title>Clinical management of emerging sinonasal malignancies.</article-title>
            <source>Head Neck</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>42</volume>
            <issue>8</issue>
            <fpage>2202</fpage>
            <page-range>2202-2212</page-range>
            <pub-id pub-id-type="pmid">32212360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Brandon</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Zanation</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Thorp</surname>
                <given-names>BD</given-names>
              </name>
            </person-group>
            <article-title>Staging of Sinonasal and Ventral Skull Base Malignancies.</article-title>
            <source>Otolaryngol Clin North Am</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>257</fpage>
            <page-range>257-271</page-range>
            <pub-id pub-id-type="pmid">28314399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nascimento</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Schembri-Wismayer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Lonzo</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-25</page-range>
            <pub-id pub-id-type="pmid">22301502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>LDR</given-names>
              </name>
              <name>
                <surname>Franchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base.</article-title>
            <source>Virchows Arch</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>472</volume>
            <issue>3</issue>
            <fpage>315</fpage>
            <page-range>315-330</page-range>
            <pub-id pub-id-type="pmid">28444451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chitguppi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koszewski</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Collura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nyquist</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rabinowitz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Biphenotypic Sinonasal Sarcoma-Case Report and Review of Clinicopathological Features and Diagnostic Modalities.</article-title>
            <source>J Neurol Surg B Skull Base</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>51</fpage>
            <page-range>51-58</page-range>
            <pub-id pub-id-type="pmid">30733901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carter</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>East</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Biphenotypic Sinonasal Sarcoma: A Review and Update.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>142</volume>
            <issue>10</issue>
            <fpage>1196</fpage>
            <page-range>1196-1201</page-range>
            <pub-id pub-id-type="pmid">30281368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DeMonte</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hanna</surname>
                <given-names>EY</given-names>
              </name>
            </person-group>
            <article-title>High-grade transformation of low-grade biphenotypic sinonasal sarcoma: Radiological, morphophenotypic variation and confirmatory molecular analysis.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>57</volume>
            <fpage>151889</fpage>
            <pub-id pub-id-type="pmid">35030392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanbazazh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jakobiec</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Orbital Involvement by Biphenotypic Sinonasal Sarcoma With a Literature Review.</article-title>
            <source>Ophthalmic Plast Reconstr Surg</source>
            <string-date>2021 Jul-Aug 01</string-date>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>305</fpage>
            <page-range>305-311</page-range>
            <pub-id pub-id-type="pmid">32991500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miglani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weindling</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Hoxworth</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Imaging characteristics and clinical outcomes of biphenotypic sinonasal sarcoma.</article-title>
            <source>Laryngoscope Investig Otolaryngol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>5</issue>
            <fpage>484</fpage>
            <page-range>484-488</page-range>
            <pub-id pub-id-type="pmid">31637290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hasnie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glenn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>JEG</given-names>
              </name>
              <name>
                <surname>El Rassi</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>High-Grade Biphenotypic Sinonasal Sarcoma: A Case Report.</article-title>
            <source>J Neurol Surg Rep</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>e105</fpage>
            <page-range>e105-e109</page-range>
            <pub-id pub-id-type="pmid">36110919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kominsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Boyke</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Madani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kamat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Biphenotypic Sinonasal Sarcoma: A Case Report and Review of Literature.</article-title>
            <source>Ear Nose Throat J</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>102</volume>
            <issue>6</issue>
            <fpage>385</fpage>
            <page-range>385-390</page-range>
            <pub-id pub-id-type="pmid">33813901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boudjadi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vemu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>The expression and function of PAX3 in development and disease.</article-title>
            <source>Gene</source>
            <year>2018</year>
            <month>Aug</month>
            <day>05</day>
            <volume>666</volume>
            <fpage>145</fpage>
            <page-range>145-157</page-range>
            <pub-id pub-id-type="pmid">29730428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146341.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chopra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamdar</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Heilbrun</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of nonsurgical management of locally advanced carcinomas of the sinonasal cavity.</article-title>
            <source>Laryngoscope</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>855</fpage>
            <page-range>855-861</page-range>
            <pub-id pub-id-type="pmid">27859278</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
